To describe imaging fi ndings of early hepatocellular carcinoma (HCC) at gadoxetic acid-enhanced magnetic resonance (MR) imaging, dynamic contrast material-enhanced computed tomography (CT), CT during arterial portography (CTAP), and CT during hepatic arteriography (CTHA) and to compare the diagnostic performance of each modality for small ( Յ 2 cm) HCC.
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Sano et al (9) (10) (11) (12) (13) . Previous reports showed that most HCCs appear as relatively lowsignal-intensity lesions at hepatocyte phase imaging because of the lack of gadoxetic acid uptake ( 11, (14) (15) (16) . Therefore, gadoxetic acid is expected to enable excellent lesion detection and characterization for both hypervascular HCCs at arterial phase imaging and hypovascular HCCs at hepatocyte phase imaging ( 17 ) . The purpose of this study was to describe imaging fi ndings of early HCC at gadoxetic acid-enhanced MR imaging, dynamic contrast-enhanced multidetector computed tomography (CT), CT during arterial portography (CTAP), and CT during hepatic arteriography (CTHA) and to compare the diagnostic performance of each modality for small ( Յ 2 cm) HCC.
Materials and Methods

Patients
The ethics committee at our institution deemed that approval of this retrospective study was unnecessary. Ninetyseven consecutive patients undergoing HCC resection at our institution from January 2008 through November 2009 were eligible for inclusion in the study.
condition ( 1, 2 ) . HCC develops in a multistep fashion from a dysplastic nodule (DN) to early HCC and, fi nally, progressed HCC ( 3, 4 ) . Among these stages, patients with early HCC show a longer time to recurrence and a higher 5-year survival rate than those with progressed HCC ( 5 ) . Therefore, the ability to detect early HCC is crucial for decreasing mortality from this neoplasm.
A great deal of confusion exists regarding the nomenclature and pathologic diagnostic criteria defi ning early HCC ( 6, 7 ) . The differences in the diagnostic criteria followed by Western and Eastern pathologists and the lack of objective and distinct pathologic fi ndings for differentiating early HCCs from DNs has made it diffi cult for hepatologists and radiologists to clarify the real imaging characteristics of early HCC and the diagnostic performance of each imaging technique for this neoplasm ( 8 ) .
After much debate, the International Consensus Group for Hepatocellular Neoplasia (ICGHN), which includes pathologists and clinicians from 13 countries, recently arrived at a consensus regarding the pathologic criteria for early HCC ( 7, 8 ) . The ICGHN stated that stromal invasion should be recognized as the most important pathologic fi nding for differentiating early HCCs from DNs. Recently, a new MR imaging contrast medium, gadoxetic acid, or gadolinium ethoxybenzyl diethylenetriaminepentaacetic (Primovist; Bayer Healthcare, Osaka, Japan ), which has properties of both an extracellular gadolinium chelate and a liver-specifi c (hepatocyte-targeting) contrast material, has become available. Injection of a bolus of gadoxetic acid allows assessment of tumor vascularity at arterial phase imaging and enables hepatic functional (ie, hepatocyte phase) imaging approximately 20 minutes after administration, with approximately 50% of the contrast material taken up by hepatocytes H epatocellular carcinoma (HCC) remains one of the leading causes of cancer-related deaths worldwide. Despite many advances in multidisciplinary treatment, complete curative treatment of early-stage HCC remains the only possibility for long-term patient survival. Although the recent evolution of diagnostic radiologic technology (eg, multidetector computed tomography [CT] or magnetic resonance [MR] imaging) has changed the landscape of hepatic imaging, only a few patients are amenable to curative treatment because the stage of HCC is usually advanced even at the fi rst documentation of the
Implication for Patient Care
The results of this retrospective n study suggest that gadoxetic acid-enhanced MR imaging is useful for detecting early HCC.
Advances in Knowledge
The The hepatocyte phase images obtained 20 minutes after injection were used for evaluation in this study. The images were acquired in the transverse plane and had a section thickness of 5 mm and a 2.5-mm overlap (ie, 2.5-mm interval). Sagittal hepatocyte phase images were also obtained once just before the axial hepatocyte phase image at 20 minutes ( Table 1 ) . Herein, T2-weighted, T1-weighted, and contrast-enhanced arterial phase, portal venous phase, late phase, and hepatocyte phase images at 20 minutes (axial and sagittal planes) are referred to as gadoxetic acid-enhanced MR images.
Contrast-enhanced CT
CT was performed by using a 16-detector row unit (Aquilion 16; Toshiba Medical Systems, Tochigi, Japan) with a tube voltage of 120 kV and tube current of 280-400 mA (automatically adjusted to the patient's body type) ( Table 2 ). Unenhanced CT scans were obtained fi rst; subsequently, a nonionic contrast medium with 600 mg iodine per kilogram body weight (Omnipaque 300, Daiichi-Sankyo, Tokyo, Japan; Iomeron 350, Eisai Global, Tokyo, Japan; Iopamiron 370, Bayer Healthcare) was After excluding nodules larger than 2.0 cm in diameter, 108 small hepatocellular lesions measuring 4-20 mm in diameter (mean diameter 6 standard deviation, 12.7 mm 6 5.0) in 64 patients were included in this study. There were 47 men (mean age, 65.6 years 6 9.5) and 17 women (mean age, 71.0 years 6 8.6); women were signifi cantly older than men ( P = .035, Mann-Whitney U test). Fifty-four of the 64 patients had Child-Pugh class A disease and 10 had class B disease. All patients underwent gadoxetic acid-enhanced MR imaging. One patient did not undergo contrastenhanced CT and CTHA-CTAP because of an allergy to the iodinated contrast material. In addition, CTHA and CTAP were not performed in one patient with mild renal dysfunction. All imaging examinations were performed within 1 month of surgery.
Liver resection was performed for the HCCs. All DNs included in this study had been considered as HCC on presurgical images or were found in the specimen by chance.
Pathologic Diagnosis
All 108 hepatocellular lesions were diagnosed strictly according to the ICGHN pathologic criteria by a liver pathologist blinded to the clinical data (M.N.), who is a member of ICGHN ( 5 ). There were 96 small HCCs and 12 DNs. The small HCCs were subdivided into two categories: progressed HCC ( n = 66) and early HCC ( n = 30) ( Fig 1 ) . A hepatocellular lesion was defi ned as early HCC if it showed a macroscopically vague nodule on the cut surface of the specimen and was defi ned as progressed HCC if it showed a distinct nodule. The progressed HCCs were further classifi ed as poorly differentiated ( n = 7), moderately differentiated ( n = 38), or well differentiated ( n = 21).
A second liver pathologist (M.S., auditing pathologist), who is also a member of ICGHN, was asked to diagnose the lesions independently to evaluate interobserver variability.
MR Imaging
Gadoxetic acid-enhanced MR imaging was performed in all patients by using
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Sano et al absence) of HCC by using a fi ve-point confi dence scale, as follows: 1 = definitely absent, 2 = probably absent, 3 = equivocal, 4 = probably present, and 5 = defi nitely present. Image interpretation was performed by using sets of the sequences and/or phases of each imaging, contrast-enhanced CT, and CTHA with CTAP (CTHA-CTAP), two other radiologists (H.S. and A.M.M., with 13 and 6 years of experience, respectively, in abdominal radiology), who were blinded to the fi nal diagnoses, independently graded the presence (or the lesion was detectable on the images. Then, the attenuation or signal intensity of the lesion was compared with that of the adjacent hepatic parenchyma for all images. Lesions were classifi ed as hyperintense and iso-to hypointense for T2-weighted MR imaging; hypointense on both in-and opposed-phase images, a fat-containing lesion when the lesion displayed a decrease in signal intensity on opposed-phase images compared with in-phase images, and iso-to hyperintense on both in-and opposed-phase images for T1-weighted MR imaging; hypointense and iso-to hyperintense for portal venous, late, and hepatocyte phases of gadoxetic acid-enhanced MR imaging; and hypoattenuating and isoto hyperattenuating for CTAP, unenhanced CT, and portal venous and delayed phases of contrast-enhanced CT.
In the evaluation of the arterial supply to the lesions at arterial phase gadoxetic acid-enhanced MR imaging, contrastenhanced CT, and CTHA, lesions were classifi ed as hypervascular, hypovascular with hypervascular foci, or hypovascular ( Fig 2 ) .
To evaluate the diagnostic performance of gadoxetic acid-enhanced MR modality, that is, all precontrast and postcontrast images for sets of gadoxetic acid-enhanced MR images and contrast-enhanced CT scans and CTHA and CTAP images for the set of CTHA-CTAP images . One image from each dynamic phase or MR sequence was selected for each lesion by coordinators (K.S. and U.M.) and provided to the readers (H.S. and A.M.M.) in random order. All interpretations were performed by using a commercially available viewer system or picture archiving and communication system (Synapse; Fujifi lm Medical, Tokyo, Japan). There was an interval of more than 1 week between the reading sessions of gadoxetic acid-enhanced MR images, contrastenhanced CT scans, and CTHA-CTAP images to reduce recall bias. For the sake of complete comparison, the two patients who did not undergo contrast-enhanced CT or CTHA-CTAP were excluded from the analysis of diagnostic performance.
Statistical Analysis
Imaging fi ndings with the three modalities were compared by using the x 2 test ( Tables 3-5 ). In the analyses, each reader's data were analyzed separately to avoid within-reader clustering. Receiver operating characteristic analysis was performed to compare the diagnostic performance of contrast-enhanced CT, gadoxetic acid-enhanced MR imaging, and CTHA-CTAP in the detection of HCC. To calculate the sensitivity, specifi city, and positive and negative predictive values for each modality, lesions assigned to grades 4 or 5 were regarded as positive for the presence of HCC. The diagnostic performance of each modality was also compared by using the McNemar test for sensitivity and specifi city or the x 2 test for positive and negative predictive values. P , .05 was considered indicative of a statistically signifi cant difference. The k value was calculated to assess interobserver and interreader variability for pathologic and radiologic diagnoses between the two pathologists and two radiologists, respectively. A k statistic in the range of 0.81-1.00 was interpreted as excellent agreement, 0.61-0.80 as substantial agreement, 0.41-0.60 as moderate agreement, 0.21-0.40 as fair agreement, and 0.00-0.20 as poor agreement. All statistical analyses were performed with software (SPSS, version 16; SPSS, Chicago, Ill).
Results
Findings with Each Imaging Modality
Unenhanced and gadoxetic acidenhanced MR imaging.-Most DNs (11 of 12 lesions, 92%) were not detected at T2-weighted imaging, whereas early HCCs were visible as areas of hyperintensity (three of 30 lesions, 10%) or iso-to hypointensity (11 of 30 lesions, 37%) ( P = .049). The appearance of a fat-containing mass on T1-weighted images was more frequently observed in early HCCs (16 of 30 lesions, 53%) than in DNs (0 of 12 lesions, 0%) and progressed HCCs (11 of 66 lesions, 17%) ( P = .001 and P , .001, respectively) ( Figs 3d, 4c ) . Early HCCs were demonstrated as hypointense to hepatic parenchyma on gadoxetic acid-enhanced MR images obtained in the hepatocyte phase (29 of 30 lesions, 97%), portal venous phase (10 of 30 lesions, 33%), and late phase (14 of 30 lesions, 47 %), whereas none of the DNs showed low signal intensity on postcontrast gadoxetic acid-enhanced MR images ( P , .001) ( Figs 3b, 3c, 4d, 5d ) . Four of the 30 early HCCs (13%) were classifi ed as hypovascular with hypervascular foci in the arterial phase (the rest of the early HCCs were hypovascular), whereas 92% of progressed HCCs (61 of 66 lesions) were entirely hypervascular ( Table 3 ) .
Contrast-enhanced CT.-At unenhanced CT, a hypoattenuating lesion compared with hepatic parenchyma was less frequently observed in DNs (0 of
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Sano et al Table 4 Findings at Contrast-enhanced CT ) were not detected at portal venous phase contrast-enhanced CT, whereas 11 (37%) and eight (26%) of the 30 early HCCs were hypo-and iso-to hyperattenuating to hepatic parenchyma ( P , .001) ( Fig 4a, 4b ). An entirely hypervascular appearance at arterial phase contrast-enhanced CT was only observed in progressed HCC (57 of 64 lesions, 89%; P , .001) ( Table 4 ) . CTHA-CTAP.-None of the DNs were hypoattenuating to hepatic parenchyma on CTAP images. Conversely, 11 of the 30 early HCCs (37%) had low attenuation ( P = .015). An entirely hypervascular appearance was observed only in progressed HCC-even at CTHA (57 of 61 lesions, 93%)-whereas 20% of 
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The ICGHN recently announced the pathologic characteristics of early HCC and objective criteria for differentiating early HCCs from DNs ( 7 ). Because of these globally approved pathologic criteria, it has become possible to perform radiologic studies for the diagnosis of early HCC. With regard to a reference standard, our study has two advantages. First, all lesions examined were resected, allowing pathologic evaluation of the entire lesion. Because the pathologic diagnosis of early HCC is based mainly on the fi nding of "stromal invasion," a biopsy specimen cannot HCCs and DNs have remained unresolved problems ( 8, 18 ) , mainly because the pathologic features of early HCCs closely resemble those of DNs. As a result, distinct and objective pathologic defi nitions and diagnostic criteria of early HCCs were not established until recently. Therefore, the results of previous reports that assessed the diagnostic performance of any imaging modality for early HCC always lacked reliability and reproducibility because of the dependence on the vague and subjective pathologic standard of reference (19) (20) (21) .
early HCCs (six of 30 lesions) and 3% of progressed HCCs (two of 61 lesions) were hypovascular with hypervascular foci at CTHA ( Table 5 ) ( Fig 5a, 5b ) . 1 and 2) ; no signifi cant difference was observed in specifi cities between gadoxetic acidenhanced MR imaging and contrastenhanced CT ( Table 6 ; Figs 3, 5 ) .
Diagnostic Performance
Contrast-enhanced CT had significantly greater specifi city (159 of 161 images, 98.8%) than CTHA-CTAP (146 of 161, 90.7%) only for reader 1.
Interobserver Variability of Pathologic and Radiologic Diagnoses
The interobserver variability between the two pathologists was excellent (mean k 6 standard error , 0.95 6 0.029) ( Figs 3e, 5e ). In three lesions, the diagnosis made by the auditing pathologist was different from that made by the two pathologists. The diagnoses of the two pathologists were the same regarding the other lesions. Even if the diagnosis of the auditing pathologist was applied as a reference standard, the conclusions of this study would not be altered.
The interreader variability between the two radiologists was excellent for gadoxetic acid-enhanced MR imaging (mean, 0.91 6 0.053) and substantial for contrast-enhanced CT (mean, 0.71 6 0.11) and CTHA-CTAP (mean, 0.788 6 0.084).
Discussion
Proper detection of early HCCs and accurate differentiation between early Note.-NPV = negative predictive value, PPV = positive predictive value.
* Numbers in parentheses are 95% confi dence intervals, and numbers in brackets are numbers of lesions .
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did not include hypovascular, or early, HCC ( 24 ) . The differentiation of early HCC from DN with superparamagnetic iron oxide is also challenging ( 25, 26 ) . Imai et al ( 27 ) concluded that differentiation between DN and HCC by the degree of uptake of superparamagnetic iron oxide was limited because the amount of Kupffer cells in a DN and a well-differentiated HCC, including early HCC, are not different. Superparamagnetic iron oxide-enhanced T2-or T2*-weighted images showed hyperintensity in DN and in well-differentiated HCC ( 27 ) . One of the major limitations of this study is the relatively small number of DNs (because we included only those nodules that were surgically resected). The biased sample of this study might bias our report of sensitivity. A different study design, such as the use of explanted liver, might provide a larger number of DNs. Another limitation is the retrospective study design. Because we evaluated only surgically removed lesions, we could not evaluate whether gadoxetic acid-enhanced MR imaging had an effect on patient care. A prospective cohort study design could clarify the clinical utility of gadoxetic acidenhanced MR imaging for early HCCs.
In conclusion, gadoxetic acidenhanced MR imaging is the most useful imaging technique for evaluating small HCCs, specifi cally owing to the high sensitivity for early HCC. suffi ciently high when the recent imaging techniques, including contrastenhanced CT or MR imaging, are applied ( 7, 8, 11, 12, (14) (15) (16) , and our results for progressed HCC are consistent with fi ndings in those previous reports. However, we obtained completely different results for early HCCs: We found that conventional imaging modalities, including contrast-enhanced CT, CTHA, CTAP, and unenhanced MR imaging, depicted only 57%-73% of early HCCs. It is not surprising that conventional arterial phase imaging techniques are not useful for evaluating early HCCs because they are always an essentially hypovascular lesion, as clarifi ed in our study. Contrarily, we found that hepatocyte phase gadoxetic acid-enhanced MR imaging is the only technique that successfully depicts early HCCs, with 29 of the 30 early HCCs visible.
There are three different types of liver-specifi c MR contrast material from gadoxetic acid, including mangafodipir trisodium, gadobenate dimeglumine, and superparamagnetic iron oxide. Although the dose, mechanism of cellular uptake, degree of excretion through the biliary pathway, and imaging characteristics of mangafodipir trisodium and gadobenate dimeglumine are different, they are taken up by hepatocytes and excreted in the bile in a similar way as gadoxetic acid. To our knowledge, no report has focused on the imaging characterization of DN, early HCC, and progressed HCC with mangafodipir trisodium. However, the degree of mangafodipir trisodium uptake in hepatocellular lesions has reportedly varied, that is, mangafodipir trisodium enhancement in HCC was not signifi cantly related to histopathologic type of HCC ( 22 ) . The differentiation between DN and early HCC with gadobenate dimeglumine has not been well studied ( 23 ) . It was reported that 1-hour delayed phase gadobenate dimeglumine-enhanced images showed different signal intensities in HCC and DN (most hypervascular, or progressed, HCCs showed low signal intensity [30 of 42, 71%]; the DN were isointense [10 of 13 lesions, 77%] or showed high signal intensity [two of 13 lesions, 15%]); however, the authors always provide suffi cient information with which to confi rm the diagnosis. Second, the fi nal pathologic diagnosis of all lesions was determined by a pathologist who is an ICGHN member and a coauthor of the ICGHN report ( 7 ) .
Several characteristic imaging features of early HCC can be established from the results of our study. First, regarding the hemodynamic characteristics of early HCC, we can conclude that early HCC is essentially hypovascular and has no dominant arterial blood supply because none of the early HCCs or DNs showed hypervascularity throughout the lesions on any arterial phase images, including contrast-enhanced CT scans, gadoxetic acid-enhanced MR images, and CTHA images. Although some early HCCs showed hypervascular foci within them, the lesions themselves were essentially hypovascular. Such an enhancement pattern may represent one of the unique pathologic features of early HCCs, a "nodule-in-nodule" appearance ( 5 ). Meanwhile, a portal blood supply was seen in 39% of the early HCCs, that is, seven of 18 early HCCs showed iso-to hyperattenuation at CTAP. Consequently, there are several particular imaging features that can help differentiate an early HCC from a DN: (a) evidence of a possible fat-containing lesion (ie, appearance of a fat-containing mass on T1-weighted MR images and low attenuation on unenhanced CT scans), (b) lesion is hyper-or iso-to hypointense to liver parenchyma on T2-weighted images, and (c) lesion has low signal intensity on gadoxetic acid-enhanced MR images obtained in the portal venous, late, and hepatocyte phase. All of these features were considerably specifi c for early HCC (compared with DNs), but only the fi ndings from gadoxetic acidenhanced MR imaging were suffi ciently sensitive. It should be noted that a lesion demonstrating hypervascularity (throughout the lesion) on any contrastenhanced arterial phase images should be defi ned as progressed HCC per the ICGHN criteria, even if the lesion is less than 2 cm in diameter.
Most previous reports revealed that the sensitivity of hypervascular HCC is
